Back

Treatment with activin type ii receptor antibody improves cardiac function in mice after myocardial infarction

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Chronic heart failure - Bench studies Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Weike Bao

AstraZeneca, Gaithersburg (United States of America)

5 More presentations in this session

Presentation thumbnail
Target induction of heme oxygenase-1 attenuates anti-HLA I antibody induced transplant vasculopathy in an allogeneic aortic transplantation model in mice
Doctor L. Kummer (Heidelberg, DE)
Abstract Slides
Presentation thumbnail
Nitro-oxidative stress impairs single cardiomyocyte adrenergic reserve in a murine model of HFpEF.
Mr L. Semmler (Berlin, DE)
Abstract Slides
Presentation thumbnail
Deletion of the extracellular matrix glycoprotein ADAMTSL3 increases pro-fibrotic signalling and exacerbates heart failure in mice
Doctor K. Rypdal (Oslo, NO)
Abstract Slides
Presentation thumbnail
Sodium glucose co-transporter 2 inhibition prevents muscle energy metabolism changes in infarcted rats
Miss L. Souza (Botucatu, BR)
Abstract Slides
Presentation thumbnail
Takotsubo syndrome-like model in rats with high reproducibility and low mortality
Doctor E. Zulfaj (Gothenburg, SE)
Abstract Slides

Access the full session

Session thumbnail
Chronic heart failure - Bench studies

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Breaking the barriers in guideline-directed medical therapy implementation in heart failure - discussion
thumbnail
Congress Presentation
The role of ICD therapy in heart failure in 2024. What is the holistic approach to treat heart failure?
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources